Literature DB >> 15735947

Percutaneous and open renal revascularizations have equivalent long-term functional outcomes.

Irfan I Galaria1, Scott M Surowiec, Jeffrey M Rhodes, Karl A Illig, Cynthia K Shortell, Yaron Sternbach, Richard M Green, Mark G Davies.   

Abstract

Atherosclerotic renal artery stenosis is a significant cause of poorly controlled hypertension and progressive renal dysfunction leading to ischemic nephropathy and other end-organ damage. The optimal treatment of renovascular disease contributing to hypertension and renal dysfunction is not known. This study compares the anatomic and functional outcomes of both open and endovascular therapy for chronic, symptomatic atherosclerotic renal artery disease. We performed a retrospective analysis of records from patients who underwent renal arterial interventions, endovascular or open bypass, between January 1984 and January 2004. Principal indications for intervention were hypertension (51%), chronic renal insufficiency (13%), and hypertension and elevated creatinine (36%). A total of 247 patients (109 males; mean age 69 +/- 10, range 44-89 years) underwent 314 interventions (109 open procedures; 205 angioplasties, 71% with stent placement). There was a significant difference in 30-day mortality (4% vs. <1%; p < 0.005) between the open and endoluminal groups, but not at 1, 3, or 5 years. Patients in the open group had a higher primary patency rate at 5 years (83 +/- 5% vs. 76 +/- 6%; p = 0.03), but patients in the endoluminal group had a higher assisted primary patency rate at 5 years (92 +/- 5% vs. 84 +/- 5; p = 0.03). There was no significant difference between both treatment groups in cumulative freedom from presenting symptom or in freedom from dialysis and renal-related death. Patients who presented with hypertension were more likely to have shown improvement in their blood pressure with endoluminal intervention at 1, 3, and 5 (59 +/- 6% endoluminal vs. 83 +/- 5% open; p = 0.01) years. From these results we conclude that open repair and endoluminal repair of atherosclerotic renal artery stenosis have similar immediate and long-term functional and anatomic outcomes. Patients who present with hypertension may have greater benefit with an endoluminal repair.

Entities:  

Mesh:

Year:  2005        PMID: 15735947     DOI: 10.1007/s10016-004-0165-8

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  8 in total

Review 1.  [Treatment of renal artery stenosis in the year 2021].

Authors:  Tomas Lenz
Journal:  Internist (Berl)       Date:  2021-01-18       Impact factor: 0.743

Review 2.  Atherosclerotic renovascular hypertension: current trends in diagnosis and management.

Authors:  Kunal Chaudhary; Joshua Botdorf; Adam Whaley-Connell
Journal:  Mo Med       Date:  2011 Jan-Feb

Review 3.  [Current management of renal artery stenosis].

Authors:  T Lenz
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

4.  Changes in glomerular filtration rate after renal revascularization correlate with microvascular hemodynamics and inflammation in Swine renal artery stenosis.

Authors:  Alfonso Eirin; Behzad Ebrahimi; Xin Zhang; Xiang-Yang Zhu; Hui Tang; John A Crane; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Circ Cardiovasc Interv       Date:  2012-10-09       Impact factor: 6.546

5.  The cardiovascular outcomes in renal atherosclerotic lesions study and the future of renal artery stenting.

Authors:  Samuel J Mann; Thomas A Sos
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-20       Impact factor: 3.738

6.  Atherosclerotic renovascular hypertension : lessons from recent clinical studies.

Authors:  Wookyung Chung; Sejoong Kim
Journal:  Electrolyte Blood Press       Date:  2010-12-31

7.  Inflammation in cardiovascular tissue engineering: the challenge to a promise: a minireview.

Authors:  Agneta Simionescu; Jason B Schulte; George Fercana; Dan T Simionescu
Journal:  Int J Inflam       Date:  2011-07-09

Review 8.  Renovascular hypertension: an update.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.